Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
13.71
+0.38 (2.85%)
At close: Jan 21, 2026, 4:00 PM EST
13.71
0.00 (0.00%)
After-hours: Jan 21, 2026, 4:04 PM EST
Amneal Pharmaceuticals Revenue
Amneal Pharmaceuticals had revenue of $784.51M in the quarter ending September 30, 2025, with 11.68% growth. This brings the company's revenue in the last twelve months to $2.93B, up 9.50% year-over-year. In the year 2024, Amneal Pharmaceuticals had annual revenue of $2.79B with 16.73% growth.
Revenue (ttm)
$2.93B
Revenue Growth
+9.50%
P/S Ratio
1.42
Revenue / Employee
$353,610
Employees
8,300
Market Cap
4.31B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.79B | 400.35M | 16.73% |
| Dec 31, 2023 | 2.39B | 181.30M | 8.20% |
| Dec 31, 2022 | 2.21B | 118.64M | 5.67% |
| Dec 31, 2021 | 2.09B | 101.15M | 5.08% |
| Dec 31, 2020 | 1.99B | 366.15M | 22.51% |
| Dec 31, 2019 | 1.63B | -36.62M | -2.20% |
| Dec 31, 2018 | 1.66B | 629.34M | 60.88% |
| Dec 31, 2017 | 1.03B | 15.43M | 1.52% |
| Dec 31, 2016 | 1.02B | 151.95M | 17.54% |
| Dec 31, 2015 | 866.28M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bausch Health Companies | 10.03B |
| Perrigo Company | 4.28B |
| Hims & Hers Health | 2.21B |
| Lantheus Holdings | 1.53B |
| Alkermes | 1.52B |
| Indivior | 1.18B |
| Prestige Consumer Healthcare | 1.11B |
| Supernus Pharmaceuticals | 681.54M |
AMRX News
- 7 days ago - Amneal Pharmaceuticals, Inc. (AMRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 12 days ago - KeifeRx Announces Research Collaboration and Option Agreement with Amneal Pharmaceuticals to Advance KFRX06, a Brain-Penetrant LRRK2 Program for Parkinson's Disease - Business Wire
- 4 weeks ago - Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA® - GlobeNewsWire
- 4 weeks ago - Amneal: Growing Drug Portfolio, Positive Cash Flow, Outweighing Leverage Risks - Seeking Alpha
- 6 weeks ago - Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals - GlobeNewsWire
- 6 weeks ago - Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson's Disease - GlobeNewsWire
- 7 weeks ago - Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol - GlobeNewsWire
- 7 weeks ago - Amneal to Participate in Upcoming Investor Conferences - GlobeNewsWire